EyePoint Pharmaceuticals Stock Gains 3% After Positive Phase 2 Trial Results

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT) is up by 3.66 percent during Monday trading, rising $0.28 to $7.90. The stock moved higher after the company announced positive six-month results from its ongoing Phase 2 VERONA clinical trial evaluating DURAVYU, vorolanib intravitreal insert, an investigational sustained delivery therapy for retinal diseases.

EYPT is currently trading at $7.80, up $0.28 from the previous close of $7.62. The stock has fluctuated today, reaching a high of $8.68 and a low of $6.60. Trading volume has surged to 2.80 million shares, significantly above the average volume of 0.84 million. The stock remains within its 52-week range of $6.60 to $30.99.

The trial met its primary endpoint, showing an extended time to first supplemental injection compared to aflibercept control across both DURAVYU doses. Additionally, the therapy demonstrated strong safety results, with no treatment-related serious adverse events, along with early and sustained improvements in vision and anatomical control.